Please assess the completion status of the following clinical trial:

Trial Title: TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with documented HIV-1 infection~* Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening~* Patient's HIV-1 plasma viral load at screening is \> 5,000 HIV-1 RNA copies/mL (assayed by RNA PCR standard specimen procedure)~* Patient's virus is sensitive to the 2 nucleoside/nucleotide reverse transcriptase inhibitors chosen for treatment~* Patient agrees not to start ART before the baseline visit~* Patient is HLA-B\*5701 negative in case abacavir is included in the patient's treatment regimen.~Exclusion Criteria:~* Previous use of ANY ARV drug for ANY length of time~* Any documented evidence of NNRTI resistance associated mutations in patient's HIV~* Category C AIDS defining illness, except, Stable Kaposi Sarcoma Wasting syndrome if not progressive~* Pneumocystis carinii pneumonia (PCP) that is considered not cured~* Active TB~* Allergy or hypersensitivity to study or background ARTs~* Specific grade 3 or 4 toxicity~* Kidney impairment: calculated creatinine clearance \<50 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 002 (Type: ACTIVE_COMPARATOR): efavirenz 600 mg tablet once daily for 96 weeks
- 001 (Type: EXPERIMENTAL): TMC278 25 mg tablet once daily for 96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).